Jerry Schloffman has joined Valencia Technologies as Chief of Market Development.
In his role, Schloffman will be responsible for generating enthusiasm and support for the use of Valencia’s coin-sized neuromodulation device in the treatment of resistant hypertension, a company spokesperson said.
He will also work on the recruitment of clinical trial sites and the recruitment of patients for the pivotal trial in the United States in 2016.
“Jerry is a perfect fit for what Valencia needs to accomplish in the next few years,” said Jeff Greiner, Valencia Technologies founder and CEO. “Moreover, Jerry’s strategic thinking, work ethic, and balance will fortify our already strong team.”
Schloffman comes to Valencia Technologies after spending the last 4 years at Cochlear Americas, a leader in implantable hearing technologies, where he was responsible for a field and operations staff of approximately 90 people and over 225 million dollars in annual revenue.
Prior to that, Schloffman spent 16 years at Advanced Bionics serving in a number of roles including the Vice President of Global Marketing and the Vice President of North American Sales and Service, reporting to Greiner.
“It took something really special to convince me to leave Cochlear Corporation,” Schloffman said. “But, I see working with Valencia Technologies as a once in a lifetime opportunity and am honored to join Jeff and the team.”
While Valencia Technologies is setting about to change the way hypertension is treated, the core technology has almost unlimited potential to treat a number of other disease states, Schloffman said.

